1 Building a Portfolio of Differentiated Specialty Therapies Investor Update | September 2026 Important Notice and Disclaimer 2 ? Nature of Document: This presentation has been prepared and issued by LTR Pharma Ltd (Company or LTP) to provide general information about the Company. The...
Investor Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from LTR Pharma
- LTR Expands Men's Health Portfolio with KYZATREX Pilot
- FY26 Results Announcement
- Appendix 4G and Corporate Governance Statement
- Appendix 4E and Annual Report to Shareholders
- SPONTAN Real-World Study Reports 93% Response
Later from LTR Pharma
- Application for quotation of securities - LTP
- Notice of Annual General Meeting/Proxy Form
- SPONTAN Phase II Final Results
- Clinical and Commercial Update - Investor Webinar
- First ROXUS Prescriptions Fulfilled in the United States
Follow LTR Pharma into a list and get an email when it puts out news.
Follow LTR Pharma